Biosortia Contract Gives Researchers Access To Natural Product Chemistry For Drug Discovery Efforts

February 22, 2016

COLUMBUS, OHIO --  Biosortia Pharmaceuticals announces today a contract with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) that gives the institution’s cancer researchers access to novel natural product chemistry for the purpose of discovering and developing cancer-fighting therapeutics.

Leveraging their areas of expertise in the discovery screening of novel natural products, the contract combines Biosortia’s proprietary natural product chemistry and expertise with OSUCCC – James researchers’ proprietary screening assays and drug development capabilities with the goal of identifying new therapeutic indications.

The agreement will give OSUCCC – James researchers access to Biosortia’s proprietary natural product chemistry molecules for the purpose of drug development studies conducted through Ohio State’s Drug Development Institute (DDI).

Created and funded by the OSUCCC – James, and with the help of seven Ohio State colleges and the university’s technology commercialization office, the DDI helps expedite cancer drug development through strategic partnerships within the global pharmaceutical and research/development industries.

"With more than 200 oncologists, each of whom specializes in just one type of cancer, the OSUCCC – James brings extraordinary sub-specialization expertise to the collaboration. We are encouraged to be working with OSUCCC – James and their dedicated researchers as we strive to deliver targeted therapies that will bring better outcomes in the fight against cancer," says Guy Carter, PhD, Biosortia chief scientific officer.

Biosortia Pharmaceuticals, a natural products drug discovery and development company, leverages nature for the discovery of first-in-class small molecules as potential solutions to high priority unmet needs that will positively impact human health. Together with OSUCCC – James, Biosortia will provide access to pre-optimized small molecule chemistry produced by unculturable aquatic microorganisms for anti-cancer drug discovery.

-30-

Media Contacts:

Amanda Harper
OSUCCC – James
614-685-5420
amanda.harper2@osumc.edu

Chad Hummell
Biosortia
614-573-1903
chummell@biosortia.com

Contact Media Staff

Amanda Harper

Director of Media Relations


614-685-5420 (direct)


614-293-3737 (main)


Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Dr. Michael Caligiuri Explains Origins of Cancer at Annual Fireside Chat

Learn about how cancer forms, as well as how the OSUCCC – James is working to develop new therapies and treatments, from Director and CEO Dr. Michael Caligiuri.

Surgical Intensive Care Unit Wins National Award for Patient Care Excellence

The OSUCCC - James surgical intensive care unit (SICU) has received national recognition for exceptional patient care and professional nursing practice with a three-year, silver level Beacon Award for...

Patient and Former NFL Player Team Up to Support Lung Cancer Research, Spread Hope

Patient Dirk Bosgraf teamed up with former NFL player Chris Draft to offer hope to other patients by raising money for lung cancer research at the OSUCCC - James.